Integrative analysis of NSCLC identifies tumor genetic profiles associated with PD-L1 expression

被引：0
|
作者：
Saigi, M. [1 ]
Pereira, C. [1 ]
Pros, E. [1 ]
Brambilla, E. [2 ]
Alburquerque, J. [1 ]
Baixeras, N. [3 ]
Sanchez-Cespedes, M. [1 ]
Nadal, E. [4 ]
机构：
[1] IDIBELL, Canc Epigenet & Biol Program, Lhospitalet De Llobregat, Spain
[2] Hop Michallon, CHU Grenoble, Pathol Dept, La Tronche, France
[3] Hosp Bellvitge ICO, Pathol Dept, Lhospitalet De Llobregat, Spain
[4] ICO, Thorac Oncol Unit, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1647P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cross-platform integrative analysis of NSCLC reveals association between PD-L1 expression patterns and tumor genetic profile
    Edwards, Robin
    Vitazka, Patrik
    Szabo, Peter
    Chang, Han
    Cogswell, John
    Tang, Hao
    Desai, Kaushal
    Locke, Darren
    Wu, Qiuyan
    Szustakowski, Joseph
    Bernstein, Steven
    Cleary, Michele
    CANCER RESEARCH, 2017, 77
  • [2] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    MODERN PATHOLOGY, 2018, 31 : 755 - 755
  • [3] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    LABORATORY INVESTIGATION, 2018, 98 : 755 - 755
  • [4] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [5] Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples
    Boothman, A.
    Scott, M.
    Ratcliffe, M.
    Whiteley, J.
    Dennis, P.
    Wadsworth, C.
    Sharpe, A.
    Rizvi, N.
    Garassino, M.
    Walker, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S422 - S422
  • [6] Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
    John, Nikolaus
    Schlintl, Verena
    Sassmann, Teresa
    Lindenmann, Joerg
    Fediuk, Melanie
    Wurm, Robert
    Douschan, Philipp
    Zacharias, Martin
    Kalson, Lipika
    Posch, Florian
    Absenger, Gudrun
    Brcic, Luka
    Jost, Philipp J.
    Terbuch, Angelika
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [7] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
    Janning, Melanie
    Kobus, Franca
    Babayan, Anna
    Wikman, Harriet
    Velthaus, Janna-Lisa
    Bergmann, Sonja
    Schatz, Stefanie
    Falk, Markus
    Berger, Lars-Arne
    Boettcher, Lisa-Marie
    Paesler, Sarina
    Gorges, Tobias M.
    O'Flaherty, Linda
    Hille, Claudia
    Joosse, Simon A.
    Simon, Ronald
    Tiemann, Markus
    Bokemeyer, Carsten
    Reck, Martin
    Riethdorf, Sabine
    Pantel, Klaus
    Loges, Sonja
    CANCERS, 2019, 11 (06):
  • [8] Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression
    Kunimasa, Kei
    Nakamura, Harumi
    Nishino, Kazumi
    Nakatsuka, Shin-ichi
    Kumagai, Toru
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E231 - E233
  • [9] PD-L1 expression in NSCLC and biopsy size
    Kern, I.
    Kovacevic, M.
    Janzic, U.
    Cufer, T.
    VIRCHOWS ARCHIV, 2016, 469 : S127 - S127
  • [10] Tumor PD-L1 expression is associated with outcomes in stage 3 NSCLC patients treated with consolidation durvalumab
    Jazieh, Khalid
    Gad, Mohamed
    Saad, Anas
    Wei, Wei
    Pennell, Nathan A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) : 3071 - 3078
12345